Phaseline

Targets › IL2

IL2 (Interleukin-2): drug programs, companies and trials

16 programs from 16 companies in 31 trials: 16 Phase 1, 11 Phase 2, 3 Phase 3, 1 Phase 4; Oncology, Immunology, Other; next expected readout Nov 2026.

Cytokine produced by activated CD4-positive helper T-cells and to a lesser extend activated CD8-positive T-cells and natural killer (NK) cells that plays pivotal roles in the immune response and tolerance. Binds to a receptor complex composed of either the high-affinity trimeric IL-2R (IL2RA/CD25, IL2RB/CD122 and IL2RG/CD132) or the low-affinity dimeric IL-2R (IL2RB and IL2RG). (UniProt, P60568)

Open in Phaseline: the race on IL2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Shanghai Pulmonary Hospital, Shanghai, ChinaVγ2Vδ2 T lymphocyte-based immunotherapy (zoledronic acid/interleukin 2)
Drug combination that amplifies Vγ2Vδ2 T cells via zoledronic acid (FDPS inhibitor) and IL
IL2, FDPSPhase 4MDR-TBAug 2027
Innovent Biologics (Suzhou)IBI363
Mutated IL-2 cytokine fused to anti-PD-1 antibody; combines IL-2 pathway stimulation with
PDCD1, IL2Phase 3Colorectal Cancer; Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer; Melanoma; Solid Tumors or Lymphoma …Nov 2026
Nektar TherapeuticsRezpegaldesleukin (NKTR-358)
Pegylated recombinant human interleukin-2
IL2RA, IL2Phase 3Moderate-to-Severe Atopic Dermatitis; Moderate to Severe Atopic Dermatitis; Type 1 Diabetes MellitusDec 2026
Coya TherapeuticsCOYA 302
Low-dose IL-2 to enhance regulatory T cell function combined with abatacept (CTLA-4 Ig) to
IL2, CD80, CD86Phase 2Amyotrophic Lateral Sclerosis (ALS)Apr 2027
Regeneron PharmaceuticalsREGN10597
PD-1-IL2Ra-IL2 immunotherapy
PDCD1, IL2RA, IL2Phase 2Ovarian Cancer; Non Small Cell Lung Cancer; MelanomaJun 2028
SalsperaSalmonella-IL2 (Saltikva)
Attenuated Salmonella Typhimurium expressing IL-2
IL2Phase 2Metastatic Pancreatic CancerDec 2030
Second Xiangya Hospital of Central South UniversityHuman interleukin-2 (IL-2)
Interleukin-2 cytokine
IL2Phase 2Chronic Spontaneous Uriticaria–
Aulos BioscienceAU-007 (imneskibart)
Monoclonal antibody that binds to IL-2 and inhibits IL-2Rα binding
IL2Phase 1Advanced Solid TumorFeb 2027
Trutino BiosciencesODC-IL2
Conditionally activated IL-2 prodrug
IL2Phase 1Advanced Solid TumorsMar 2027
Asher Biotherapeuticsetakafusp alfa (AB248)
CD8+ T cell selective interleukin-2 agonist
IL2Phase 1Solid TumorMay 2027
HCW BiologicsHCW9302
IL-2 fusion protein
IL2Phase 1Alopecia Areata(AA)Jul 2027
Ascendis Pharma Oncology DivisionTransCon IL-2 β/γ
IL-2 receptor agonist with extended half-life via TransCon technology
IL2Phase 1Advanced Solid TumorAug 2027
Medicenna TherapeuticsMDNA11
Beta-only IL-2 receptor agonist fused to albumin
IL2Phase 1Advanced Solid TumorOct 2028
SynthekineSTK-012
Engineered Interleukin-2 (IL-2) selective for antigen-activated T cells
IL2Phase 1Advanced Solid TumorJan 2029
AstraZenecaAZD6750
CD8-targeted IL-2 immunomodulator
IL2Phase 1MelanomaOct 2029
Iovance BiotherapeuticsIOV-3001
Modified interleukin-2 fusion protein
IL2Phase 1Unresectable MelanomaJun 2032

Conditions

Advanced Solid Tumor (6) Melanoma (5) Moderate-to-Severe Atopic Dermatitis (2) Colorectal Cancer (1) Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer (1) Solid Tumors or Lymphoma (1) Solid Malignancies or Lymphomas (1) Advanced Malignancies (1) IBI363 + Chemotherapy (1) Amyotrophic Lateral Sclerosis (ALS) (1) Moderate to Severe Atopic Dermatitis (1) Type 1 Diabetes Mellitus (1)

Modalities

mixed (8), protein or peptide (5), small molecule (3)

Companies

Innovent Biologics (Suzhou) (1) AstraZeneca (1) Medicenna Therapeutics (1) Coya Therapeutics (1) Synthekine (1) Nektar Therapeutics (1) HCW Biologics (1) Shanghai Pulmonary Hospital, Shanghai, China (1) Asher Biotherapeutics (1) Regeneron Pharmaceuticals (1) Salspera (1) Iovance Biotherapeutics (1) Aulos Bioscience (1) Second Xiangya Hospital of Central South University (1) Ascendis Pharma Oncology Division (1) Trutino Biosciences (1)

Related targets

PDCD1 (2) IL2RA (2) CD80 (1) CD86 (1) FDPS (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.